Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.
Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, Gibbons DL, Lee JJ, Wu J, Vokes NI, Heymach JV, Zhang J, Le X.
Hong L, et al. Among authors: kemp hn.
Cancers (Basel). 2022 Jul 17;14(14):3473. doi: 10.3390/cancers14143473.
Cancers (Basel). 2022.
PMID: 35884533
Free PMC article.